Open-label Phase Iv Study To Investigate The Seropersistence Of Tick-borne Encephalitis (Tbe) Virus Antibodies After The First Booster And The Response To A Second Booster Vaccination With Fsme-immun In Children, Adolescents And Young Adults (Follow-up To Study 700401)
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis; Encephalitis virus infections
- Focus Pharmacodynamics
- Sponsors Pfizer
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Jul 2017 This trial has been completed in Austria.
- 18 May 2017 This trial has been completed in Poland.